MTN researchers have completed a Phase 1 study (MTN-030/IPM 041) of a dual-purpose ring using dapivirine for HIV prevention plus levonorgestrel for contraception. The study enrolled 24 cisgender women at the University of Pittsburgh and the University of Alabama at Birmingham, and was conducted in close collaboration with the nonprofit International Partnership for Microbicides (IPM), who also developed the ring. Data is currently being analyzed, with results of the study expected by mid-2018.